PhRMA CEO Steve Ubl discusses, PBM reform, the "pill penalty" with the administration and advocating for pharmaceutical ...

Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

When the 340B program was first launched, pharmaceutical manufacturers were to provide medications at a discounted price for ...

The DOJ backs Medicare price negotiations amidst a Novartis lawsuit, while President Trump vows to lower U.S. drug costs.

Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

A new study from the USC Schaeffer Center shows that out-of-pocket costs for brand-name medications have increased sharply ...

The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...

Debate over whether or not the Affordable Care Act, commonly known as Obamacare, worked and how President Trump's executive ...

Topline: Taxpayers spent $74.5 million to help develop the prostate cancer-fighting drug Xtandi, but its sky-high sticker ...

Manufacturers of medicines, including Pfizer and Eli Lilly, have spent a combined $450,000 lobbying against price caps on ...

The Maryland House of Delegates has voted overwhelmingly to allow a state board to extend its mandate for lowering ...